Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
about
Practical combination therapy based on pathophysiology of type 2 diabetesPersonalized medicine in Type 2 DiabetesPharmacogenomics of Drug Response in Type 2 Diabetes: Toward the Definition of Tailored Therapies?KCNJ11, ABCC8 and TCF7L2 polymorphisms and the response to sulfonylurea treatment in patients with type 2 diabetes: a bioinformatics assessment.Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.Association of Geroprotective Effects of Metformin and Risk of Open-Angle Glaucoma in Persons With Diabetes Mellitus.Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes.Pharmacokinetic interaction of curcumin and glibenclamide in diabetic rats.Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design.Patterns of weight change after the diagnosis of type 2 diabetes in Scotland and their relationship with glycaemic control, mortality and cardiovascular outcomes: a retrospective cohort study.Computational Analysis of Single Nucleotide Polymorphisms Associated with Altered Drug Responsiveness in Type 2 DiabetesCYP2C93 variant is associated with antidiabetes efficacy of gliclazide in Chinese type 2 diabetes patientsIndividualized treatment of type 2 diabetes mellitus using noninsulin agents: clinical considerations for the primary care physician.The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.The central question of type 2 diabetes.Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia.Using Personalized Medicine in the Management of Diabetes Mellitus.Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.Subclinical Doses of ATP-Sensitive Potassium Channel Modulators Prevent Alterations in Memory and Synaptic Plasticity Induced by Amyloid-β.Effect of gemigliptin on glycaemic variability in patients with type 2 diabetes (STABLE study).CYP2C9, KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea treatment in type 2 diabetes patients.Genetic variability of CYP2C9*2 and CYP2C9*3 in seven indigenous groups from Mexico.Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.The potential for interaction of tolbutamide with pomegranate juice against diabetic induced complications in rats.
P2860
Q28076530-72A2F8B3-C04D-4A35-AB53-C1BE23E1C67EQ28542708-DBA9A0FE-2FBD-45D2-A72D-8A1A50866875Q30388214-C2FAEBA9-0038-43B8-8564-DFC12B6EF5B4Q33771570-C6B64A4B-0BE2-48B2-8AE3-BD548437EB8BQ34392375-9C6E4B56-1EBA-431F-B82E-8D21E027B2CEQ35956368-2C609EF9-28AA-4555-B045-BF6C351EBDD6Q36376273-B8725BA7-1042-4496-BFF1-24B332737901Q36437420-9D676C7F-784C-4DA0-9EA9-1005BEAE3A2AQ36641349-858A08C7-2016-47D2-BF3D-2C4D382C3A43Q37097189-4386B1F2-1D38-4413-B04C-737A00C2E451Q37133779-5984D230-8FC8-4AD2-BB59-0F330BEF0BD3Q37134345-4EC63CF1-CE03-43F9-A468-365456017F6DQ37227417-91575F49-ECD3-42E7-93A8-42FE2FCCB4FCQ38036773-89A5F384-39FB-4101-A607-ED09E3249BB4Q38110432-C5535BFE-ED38-4993-8B71-CAC98210FE20Q38162978-23FF3AC4-62B3-4DB8-9EF1-205D2C3F1835Q38234927-84F94079-557E-4995-A003-5A4CF19BFFB8Q38666166-AB3DB05C-DA15-4D46-845C-F580B0D397EDQ38711541-E0978A20-9D23-4FB7-9CE3-43B7A4EB9C7BQ43419612-FBBA47F8-481A-46E8-8521-72956CB3510BQ47963951-1056B817-ED81-4628-9A5D-5DD07B8DCF1FQ48089021-070EDE45-9A0E-4554-9521-EF8D5E80423DQ51328309-7DC0A375-1846-4C5E-9398-774AE203C7EBQ51743967-DA14FDDF-0D46-4C62-922C-2E35E58CEDD1Q52657004-693863C2-A55D-4E22-9D74-E2D5B254A8FBQ55041802-B3DE76BD-1C6E-475B-8C78-C08141E426F6
P2860
Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@ast
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@en
type
label
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@ast
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@en
prefLabel
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@ast
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@en
P2860
P356
P1476
Sulfonylurea pharmacogenomics ...... d diabetes risk polymorphisms.
@en
P2093
Christina L Aquilante
P2860
P304
P356
10.1586/ERC.09.154
P577
2010-03-01T00:00:00Z